



DEPARTMENT OF COMMERCE

Patent and Trademark Office

COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE FIRST NAMED		IVENTOR		ATTO	ATTORNEY DOCKET NO.	
9/599,220	06/22/00	DOUGAN		Α	4041	5-0109P	
_			7 [EXAMINER			
02292	er tara Armati i	HM12/0914		MEGAR	BV S		
IRCH STEWAR O BOX 747	H RULADUM A	A DOLFALLIA	. [ART L		PAPER NUMBER	
ALLS CHURCH	VA 22040-	3747 3747		1635 DATE MA		/14/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED ATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

1635

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLIC	ANT ATT	ORNEY DOCKET NO.	
09/599,220					
			EXAMINER		
			McGarry		
			ART UNIT	PAPER NUMBER	

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Please note nucleic acid sequences on page5, for example.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Sean McGarry whose telephone number is (703) 305-7028. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner john LeGuyader whose telephone number is (703) 308-0447. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Sean McGarry September 10, 2001

> SEAN McGARRY PRIMARY EXAMINER

Application N	<u> 09</u>	<u>/59</u>	9	,220
---------------	------------	------------	---	------

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

ng r	eason(s):	
X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 11 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).	14
X	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).	€
x	 A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). 	у
x	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."	
	5. The computer readable form that has been filed with this application has been found to be damage and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	ed
	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
	7. Other:	
Αp	olicant Must Provide:	
 X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	
\boxtimes	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its e into the specification.	ntry
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).	
Fo	questions regarding compliance to these requirements, please contact:	
Fo	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212	
P8	tentIn Software Program Support Technical Assistance703-287-0200 To Purchase PatentIn Software703-306-2600	

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY